Zobrazeno 1 - 10
of 85
pro vyhledávání: '"D, Tegzová"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
S. Sheikh, M. Scheinberg, J. C. C. Wei, D. Tegzová, W. Stohl, R. Acayaba De Toledo, T. Mucenic, M. R. Abello Banfi, K. Maksimowicz-Mckinnon, C. Abud-Mendoza, S. Navarra, M. García, I. Garcia-De La Torre, A. Liu, A. Roy, P. Wilde, S. Fernandes, J. Harris, D. Roth
Publikováno v:
Annals of the Rheumatic Diseases. 81:637-638
BackgroundBelimumab (BEL) is an approved systemic lupus erythematosus (SLE) treatment. Despite BEL clinical studies demonstrating a favourable benefit–risk profile, varying incidence rates of mortality and adverse events of special interest, includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca3e087d2cb33ad0deb886bbd9d42ee9
https://doi.org/10.1136/annrheumdis-2022-eular.1993
https://doi.org/10.1136/annrheumdis-2022-eular.1993
Autor:
Adela Navrátilová, Hana Hulejová, Jiří Vencovský, L. Andres Cerezo, D. Tegzová, Karel Pavelka, Ladislav Šenolt, M. Olejarova, V. Becvar, David Veigl
Publikováno v:
Annals of the Rheumatic Diseases. 80:424.1-424
Background:Interleukin 40 (IL-40) is newly identified B cell - associated cytokine implicated in humoral immune responses and in B cell development. As B cells play a pivotal role in autoimmunity, we aimed to investigate the function of IL-40 in rheu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::518eeb3ab04c3226e5f016933c303f7d
https://doi.org/10.1136/annrheumdis-2021-eular.2339
https://doi.org/10.1136/annrheumdis-2021-eular.2339
Autor:
C. Dostál, J. Hána, Ivan Rychlik, J. Rovensky, D. Tegzová, Romana Rysava, J. Lukac, Vladimir Tesar, M. Olejarova, Z. Hrnčiř, J. Bohmova, J. Zadražil, Satu Sinikka Pesickova, J. Vitova, Pavel Horák, Jakub Zavada, Martin Havrda
Publikováno v:
Lupus. 19:1281-1289
Intravenous cyclophosphamide is considered to be the standard of care for the treatment of proliferative lupus nephritis. However, its use is limited by potentially severe toxic effects. Cyclosporine A has been suggested to be an efficient and safe t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4e3feb6c90cbf68696977bbb923fbe4
https://doi.org/10.1177/0961203310371155
https://doi.org/10.1177/0961203310371155
Publikováno v:
ResearcherID
Rheumatology International
Rheumatology International, Springer Verlag, 2010, 31 (9), pp.1195-1201. ⟨10.1007/s00296-010-1431-4⟩
Rheumatology International
Rheumatology International, Springer Verlag, 2010, 31 (9), pp.1195-1201. ⟨10.1007/s00296-010-1431-4⟩
International audience; The genetic components contribute to the systemic lupus erythematosus development. This study for the first time determined the distribution of the polymorphisms and linkage disequilibrium in HLA class II, MICA and PRL gene am
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8efd2c19903d76df3e9f1c5c01a012a
https://doi.org/10.1007/s00296-010-1431-4
https://doi.org/10.1007/s00296-010-1431-4
Autor:
J. Lukac, Z Hrncír, Jakub Zavada, S Sinikka Pesicková, M. Olejarova, Martin Havrda, J. Rovensky, Romana Rysava, Ivan Rychlik, J. Bohmova, Pavel Horák, J. Vitova, V Vlasáková, Vladimir Tesar, Josef Zadrazil, J Slatinská, D. Tegzová
Publikováno v:
Lupus. 23(1)
Objective To evaluate the extended follow-up of the CYCLOFA-LUNE trial, a randomized prospective trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide (CPH) or c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2df64cb0f54ed5be9bddee053d0a1cbf
https://pubmed.ncbi.nlm.nih.gov/24213308
https://pubmed.ncbi.nlm.nih.gov/24213308
Autor:
Christian Probst, Petra Nytrova, Jakub Zavada, R. Svobodova, Karel Pavelka, Jiří Vencovský, Klaus-Peter Wandinger, V. Peterová, D. Tegzová, Sven Jarius
Publikováno v:
Rheumatology international. 33(1)
Neuropsychiatric manifestations are present in 30–40% of patients with systemic lupus erythematosus (SLE). Recently, antibodies to aquaporin-4 (termed AQP4-Ab, or NMO-IgG), a water channel protein, were reported to be present in a subset of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5306e1d3caec864df6289d38df3ba4e
https://pubmed.ncbi.nlm.nih.gov/22038193
https://pubmed.ncbi.nlm.nih.gov/22038193
Autor:
V Peterová, Satu Sinikka Pesickova, Karel Pavelka, Lucie Muchová, Libor Vítek, D. Tegzová, Eva Jancova, Vladimír Tesař, Harvey A. Schwertner
Publikováno v:
Scopus-Elsevier
Systemic lupus erythematosus (SLE) is accompanied by severe oxidative stress. Bilirubin has been reported as a strong negative predictor of oxidative stress-mediated diseases, such as atherosclerosis. The objective of our study was to evaluate the as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a41278ec533bc2be7ae9ef7617edf29
https://pubmed.ncbi.nlm.nih.gov/20604673
https://pubmed.ncbi.nlm.nih.gov/20604673
Autor:
L, Podrazilová, V, Peterová, M, Olejárová, D, Tegzová, J, Krásenský, Z, Seidl, P, Kozelek, C, Dostál
Publikováno v:
Clinical and experimental rheumatology. 26(4)
The aim of our study was to determine the volume of pathological foci in the brain tissue of patients suffering from systemic lupus erythematosus (SLE) with or without neuropsychiatric manifestations (NP), and also to find out if that volume depends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e75457d72b1c06b209bc44e1cf4f3de7
https://pubmed.ncbi.nlm.nih.gov/18799091
https://pubmed.ncbi.nlm.nih.gov/18799091
Autor:
K, Pavelka, J, Gatterová, D, Tegzová, K, Jarosová, J, Tomasová Studýnková, A, Svobodník, J, Svihálek, L, Dusek, J, Vencovský
Publikováno v:
Clinical and experimental rheumatology. 25(4)
To evaluate the clinical status and radiographic progression in patients with rheumatoid arthritis (RA) being followed by the Czech National Registry of biological treatments.Patients who failed at least two disease-modifying antirheumatic drugs and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b44d0350aa3047cfa28bb4dde3699090
https://pubmed.ncbi.nlm.nih.gov/17888209
https://pubmed.ncbi.nlm.nih.gov/17888209